Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005167:Factor VII / Q000008:administration & dosage* / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000097:blood* / Q000627:therapeutic use; D013916:Thrombelastography / Q000379:methods; D013917:Thrombin / Q000378:metabolism; D014914:Whole Blood Coagulation Time / Q000379:methods*
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D013917:Thrombin